- Home
- HURN vs NVCR Comparison
HURN vs NVCR Comparison
Compare HURN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- NVCR
- Stock Information
- Founded
- HURN 2002
- NVCR 2000
- Country
- HURN United States
- NVCR Jersey
- Employees
- HURN N/A
- NVCR N/A
- Industry
- HURN Professional Services
- NVCR Medical/Dental Instruments
- Sector
- HURN Consumer Discretionary
- NVCR Health Care
- Exchange
- HURN Nasdaq
- NVCR Nasdaq
- Market Cap
- HURN N/A
- NVCR 1.8B
- IPO Year
- HURN 2004
- NVCR 2015
- Fundamental
- Price
- HURN $115.91
- NVCR $17.49
- Analyst Decision
- HURN Strong Buy
- NVCR Buy
- Analyst Count
- HURN 4
- NVCR 5
- Target Price
- HURN $131.75
- NVCR $26.60
- AVG Volume (30 Days)
- HURN 66.1K
- NVCR 1.3M
- Earning Date
- HURN 10-29-2024
- NVCR 10-30-2024
- Dividend Yield
- HURN N/A
- NVCR N/A
- EPS Growth
- HURN 14.29
- NVCR N/A
- EPS
- HURN 4.16
- NVCR N/A
- Revenue
- HURN $1,425,021,000.00
- NVCR $549,964,000.00
- Revenue This Year
- HURN $11.16
- NVCR $16.23
- Revenue Next Year
- HURN $8.65
- NVCR $6.09
- P/E Ratio
- HURN $25.27
- NVCR N/A
- Revenue Growth
- HURN 12.76
- NVCR 8.33
- 52 Week Low
- HURN $84.26
- NVCR $10.87
- 52 Week High
- HURN $115.65
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- HURN 66.87
- NVCR 43.24
- Support Level
- HURN $103.24
- NVCR $15.61
- Resistance Level
- HURN $108.75
- NVCR $17.31
- Average True Range (ATR)
- HURN 2.06
- NVCR 1.29
- MACD
- HURN 0.22
- NVCR 0.05
- Stochastic Oscillator
- HURN 100.00
- NVCR 11.59
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.